Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Q1 FY27 Earnings Presentation
30 slides from Poly Medicure's earnings presentation, Aug 7, 2026
Slide 1: Submission of Investor's Presentation cover letter
Poly Medicure Limited Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate, »|POLYMED Phase-lll, New Delhi - 110 020 (INDIA) T:491-11- 33550700, 47317000 E: info@polymedicure.com W: polymedicure.com CIN: L 40300DL1995PLC066923 Date: 07t August, 2026 Scrip Code: - 531768 Scrip Code:- POLYMED The M
Slide 2: Investor Presentation: Financial Results - Q1 FY27
Investor Presentation : Financial Results - Q1 FY27 August 7, 2027 1
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Poly Medicure Limited (the "Company"), content of which was compiled from sources believed to be reliable for informational purposes only and are based on information regarding the Company and the economic, regulatory, market and other conditions as
Slide 4: Company Overview
Company Overview
Slide 5: Polymed at a Glance
Polymed at a Glance 2nd Largest Medical Devices Player in India | Largest Exporter of Medical Consumables Figs in Rs. Crs unless specified PRODUCT PORTFOLIO Infusion 15 225+ 125+ Therapy Safety IV Prefilled Needle Free Three Way Stop Cock Closed Wound Manufacturing Medical Countries Endotracheal Fis
Slide 6: Polymed Flywheel
Polymed Flywheel Integrated business model serving customers globally Clinical Engagement In-House Product R&D • 60+ clinical experts; • 390+ patents • 4,000+ annual customer • 30+ new products launches annually engagement programs globally • 90+ R&D professionals Distribution Network Manufacturing,
Slide 7: Diversified Segment and Geographic Mix
Diversified Segment and Geographic Mix Rising contribution from New Segments | Deepening Presence in the Indian Market Segmental Revenue Mix Figs in Rs. Crs unless specified PORTFOLIO MIX Particulars FY20 FY 22 FY 24 FY26 CAGR (20-26) 28% 37% Infusion Therapy 466 555 925 997 14% 4% 10% Renal 26 60 9
Slide 8: Moving up the value Chain
Moving up the value Chain From essential consumables to advanced Medical Technologies • Acquired Citieffe • Entered cardiology in 2024 • Overtime to create a • Launched DES in India in 2025 comprehensive portfolio • Initiated a 2000 patient clinical trial in India and Europe in 2025 Focused on produ
Slide 9: A 30 years compounding story – Growth Engine Just warming up
A 30 years compounding story – Growth Engine Just warming up Proven yesterday. Scaling today. Defining tomorrow. P O L Y MED 1.0 P O LYMED 2.0 P O LYMED 3.0 Foundation Inflection Ascent FY 1996–2020 FY 2020–2026 FY 2027 onwards • IPO 1996 (Rs 55 Lakhs) • First Institutional Raise (Rs 1,400 cr) • Unl
Slide 10: Polymed 1.0 (1996 to 2020): Foundation
Polymed 1.0 (1996 to 2020): Foundation Resiliently built a global medical device platform with equity infusion of INR 5.5mn ~25 years | Dedicated Focus | Bootstrapped From INR 5.5 Mn IPO in 1996 built a globally competent infusion therapy platform Growth Funded by Internal Accruals Manufacturing Foo
Slide 11: Polymed 2.0 (2021 to 2026): Inflection
Polymed 2.0 (2021 to 2026): Inflection The inflection: capital, capacity, categories, countries — all scaling in parallel INR 14 Bn Institutional Equity Raised | Portfolio Expansion Growth Capital utilized towards capacity expansion, deeper penetration in Renal & Critical Care, alongside venturing i
Slide 12: Polymed 3.0 (2027 onwards): Inflection
Polymed 3.0 (2027 onwards): Inflection The next chapter isn’t incremental - it’s exponential ! Vision 2030 2.0x Revenue | Industry-leading margins | Globalization of the Business Model Climb the Tech Ladder Business Expansion • Double R&D spend • 2 upcoming plants • Globalize high-complexity vertica
Slide 13: Plan1Health
Plan1Health Since 1995 | Italy | Acquired 100.0% in 2019 | EV ~Euro 4.2 Mn 1 WHAT WE ACQUIRED? 2 WHY WE ACQUIRED? 3 SYNERGIES REALISED ▪ Entry into Critical Care segment ▪ Integrated developer & seller of long- ▪ Access to clinical data and technology 3.2x 11.8x +970 BPS term infusion devices, oncol
Slide 14: PendraCare Group – Unique Cardiology Catheter Platform
PendraCare Group – Unique Cardiology Catheter Platform Since 2011 | Netherlands | Acquired 90.0% in 2025 | EV : Euro 18.8 Mn 50+ 50+ 1,150 m² 3,800 m² 1.5M+ 65+ Countries Distributors Cleanroom 3 Leased Facilities Capacity/year Employees A Unique & One of the few ACQUISITION RATIONALE independent bi
Slide 15: Citieffe - Fully integrated supplier of high-quality Trauma Implants
Citieffe - Fully integrated supplier of high-quality Trauma Implants Since 1962 | Italy | Acquired 100.0% in 2025 | EV ~Euro 31.0 Mn 30+ 25+ 45+ 2,100 m² 85.0%+ 90+ Countries Distributors Patents 2 manufacturing Sales from countries Employees facilities with direct presence R&D (5+) & KOL (50+) A fu
Slide 16: Robust Financial Performance Delivering Strong TSR
Robust Financial Performance Delivering Strong TSR Margin% Revenue from operations (INR Cr) Gross Profit (INR Cr) Operating EBITDA (INR Cr) 2.0x 2.2x 2.1x 1,875 68.2% 24.4% 26.2% 64.9% 1,278 500 458 1,376 450 62.3% 400 23.4% 361 893 350 923 300 575 250 216 200 150 100 50 0 FY22 FY24 FY26 FY22 FY24 F
Slide 17: Strong Promoters and Experienced Leadership Team
Strong Promoters and Experienced Leadership Team Promoters Experienced Leadership Team Mr. Himanshu Baid Mr. Alessandro Balboni Mr. Sujit Gupta (Managing Director) (Non-Executive Non-Independent Director) (Senior Vice President & Head International Co-founder of Poly Medicure, Mr. Baid has over Mr.
Slide 18: Robust Governance Framework
Robust Governance Framework Non-Executive Board Mr. Devendra Raj Mehta Mr. Vishal Gupta (Chairman, Non-Executive Non-Independent Director) (Non-Executive Independent Director) A seasoned IAS officer and former Chairman of SEBI, Mr. Mehta Mr. Vishal Gupta is the Managing Director of Ashiana Housing L
Slide 19: Awards & Accolades
Awards & Accolades Himanshu Baid, MD, Poly Himanshu Baid, MD, Poly Medicure Medical Devices Provider of Best CSR Initiative in Healthcare, Hurun India 2025 List of Medicure, Healthcare Healthcare Entrepreneur of the the Year 2025 by Financial Express Education & Social Welfare India's 500 Most Valua
Slide 20: Towards our Commitment to a Sustainable World
Towards our Commitment to a Sustainable World ➢ Approx. 70% facilities are certified under ➢ Reduced Scope 2 emissions by 8% ISO 14001:2015 compared to FY 24-25 ➢ Enabled by greater utilization of solar ENVIORNMENTAL power and renewable energy PPAs MANAGEMENT SYSTEM SCOPE 2 EMISSION ➢ Annual Health
Slide 21: Financial Results & Key Updates – Q1 FY27
Financial Results & Key Updates – Q1 FY 27
Slide 22: Financial Performance Summary Q1 FY27
Financial Performance Summary Q1 FY27 Figs in Rs. Crs unless specified Acquisition Impact Margin,% Revenue Gross Profit Operating EBITDA1 68.2% 71.5% 26.5% 28.0% Standalone 431.1 308.3 120.8 384.0 262.0 101.7 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Revenue Gross Profit Operating EBITDA1 68.4
Slide 23: Key Updates
Key Updates ▪ Appointed Mr. Indranil Mukherjee as CEO – India & APAC (Ex. B Braun & Translumina) ▪ Appointed Mr. Renato Rocha as CEO (effective August 2026) of Polymed Brazil (Ex Descarpack, B.Braun & GE Healthcare) Key Business ▪ Appointed Abhimanyu Hooda as Head of Renal Business in India (Ex: Nip
Slide 24: Financial Performance Analysis
Financial Performance Analysis
Slide 25: Standalone Financial Performance Summary
Standalone Financial Performance Summary Figs in Rs. Cr. unless specified Particulars Q1 FY 27 Q1 FY 26 YoY Growth % Revenue from Operations 431.1 384.0 12.3% -Domestic 146.0 125.7 16.2% -International 281.8 256.0 10.1% -Other Operating revenue 3.3 2.4 34.6% Cost of Good Sold 122.8 122.1 0.6% Gross
Slide 26: Consolidated Financial Performance Summary
Consolidated Financial Performance Summary Figs in Rs. Cr. unless specified Particulars Q1 FY 27 Q1 FY 26 YoY Growth % Revenue from Operations 525.4 403.2 30.3% Cost of Good Sold 139.7 127.2 9.8% Gross Profit 385.6 276.0 39.7% Gross Profit % 73.4% 68.4% 495 bps Employee Benefit Expenses 126.9 74.4 7
Slide 27: Consolidated Sales Performance Analysis
Consolidated Sales Performance Analysis Figs in Rs. Cr. unless specified Consolidated Organic Particulars Q1 FY 27 Q1 FY 26 YoY Growth % Q1 FY27 YoY Growth % Domestic 146.0 125.7 16.2% 146.0 16.2% International 376.1 275.1 36.7% 303.8 10.4% Other Operating Revenue 3.3 2.4 34.6% 3.3 34.6% Total Opera
Slide 28: Segment Wise Sales Performance Analysis
Segment Wise Sales Performance Analysis Figs in Rs. Crs unless specified Infusion Therapy Q1 FY27 Q1 FY26 YoY Growth % ▪ Delivered strong growth in the domestic market led by Infusion Therapy 259.2 233.3 11.1% increasing share of higher value added products and Orthopaedics 49.2 - - price hikes Rena
Slide 29: Shareholding Pattern as on 30th June 2026
Shareholding Pattern as on 30th June 2026 Bodies Corporate, Top 10 Institutional Shareholders 2.73% Sr. No Name % Shareholding Individual, 13.05% 1 Quant Mutual Fund 4.6% Any Other, 0.15% 2 Lighthouse 2.3% AIF, 3.48% 3 Axis Max Life Insurance 2.1% 4 UTI Asset Management 2.0% Insurance 5 WhiteOak Cap
Slide 30: Thank You
Thank YouThank You For any investor related queries reach us at: Apoorv.Rastogi@polymedicure.com